<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 30, 1996
ULTRAFEM, INC.
------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-27576 33-0435037
-------------------- ------------------ ------------------
(State or other jurisdiction (Commission File Number) IRS Employer
of incorporation) Identification No.)
500 Fifth Avenue, Suite 3620, New York, New York 10110
------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (212) 575-5740
NOT APPLICABLE
-------------------------------------------------------------
(Former name or former address, if changed since last report)
-2-
<PAGE>
ITEM 5. OTHER EVENTS.
On October 30, 1996, Ultrafem, Inc. (the "Company") issued the
press release (the ""Press Release'') annexed as an exhibit hereto. The Press
Release is incorporated herein by reference.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) EXHIBITS.
99.1 Press Release of Ultrafem, Inc. dated October 30, 1996.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ULTRAFEM, INC.
(Registrant)
Dated: October 30, 1996 By: /s/ Dori M. Reap
-------------------------------
Dori M. Reap
Senior Vice President, Finance
and Administration, Secretary
and Chief Financial Officer
-3-
<PAGE>
INDEX TO EXHIBITS
EXHIBIT NO. PAGE NO.
- ----------- --------
99.1 Press Release of Ultrafem, Inc.
dated October 30, 1996
-4-
<PAGE>
EXHIBIT 99.1
CONTACT:
Philip Thomas
The PL Thomas Group
212/575-5740 or 312/906-8060
FOR IMMEDIATE RELEASE:
- ----------------------
ULTRAFEM RECEIVES CONFIRMATION FROM FDA IN SUPPORT
OF EXTENDED 12 HOUR WEAR TIME FOR INSTEAD -TM-
NEW YORK, NEW YORK, OCTOBER 30, 1996 -- Ultrafem, Inc. (NASDAQ:UFEM) today
announced that it had received a letter from the FDA confirming that Ultrafem
can market the INSTEAD-TM- feminine protection cup for use for a maximum
wear time of twelve hours. The Company had previously stated that it had
conducted and submitted to the FDA a clinical study to support the safety of
the twelve hour wear time, which it had voluntarily discussed with the FDA at
a meeting prior to finalizing the change in labeling. While the FDA was not
required to respond to the submission, the FDA's letter was made in response
to the Company's submitting results of its clinical testing.
Untrafem is a women's health care company. The Company's business strategy is
to develop, manufacture and market proprietary products based on its patented
SoftCup--REGISTERED TRADEMARK-- Technology directed at high potential,
underserved segments of the women's health care market. The Company completed
an initial public offering in February 1996 to initiate the launch of its
first commercial product, INSTEAD-TM-.
###
